Intelligence · Clinical Pipeline
TG THERAPEUTICS Pipeline
All ClinicalTrials.gov programs at TG THERAPEUTICS — phase, modality, and trial IDs.
- Programs
- 9
Quick answer
TG THERAPEUTICS has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Fingolimod placebo, FINGOLIMOD, Ublituximab Placebo, ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
1 trial -
Obinutuzumab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis (RMS)
3 trials -
Ublituximab
TG THERAPEUTICS, INC.
Chronic Lymphocytic Leukemia
5 trials -
Ublituximab
TG THERAPEUTICS, INC.
Diffuse Large B-Cell Lymphoma
1 trial -
Ublituximab
TG THERAPEUTICS, INC.
Relapsing Multiple Sclerosis
3 trials -
Ublituximab, ublituximab
TG THERAPEUTICS, INC.
Relapsing forms of Multiple Sclerosis
1 trial -
ublituximab
TG THERAPEUTICS, INC.
relapsing multiple sclerosis
1 trial -
ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE
TG THERAPEUTICS, INC.
Relapsing multiple sclerosis
1 trial
Frequently asked questions
How many pipeline programs does TG THERAPEUTICS have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs